| 1 |
Torre LA, Bray F, Siegel RL, et al. Global cancer statistics[J]. CA Cancer J Clin, 2015, 65(2): 87-108.
|
| 2 |
Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37513025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries[J]. Lancet, 2018, 391(10125): 1023-1075.
|
| 3 |
Zhang T, Wan B, Zhao Y, et al. Treatment of uncommon EGFR mutations in non-small cell lung cancer: New evidence and treatment[J]. Transl Lung Cancer Res, 2019, 8(3): 302-316.
|
| 4 |
Shimoji M, Nakajima T, Yamatani C, et al. A clinicopathological and immunohistological re-evaluation of adenosquamous carcinoma of the lung[J]. Pathol Int, 2011, 61(12): 717-722.
|
| 5 |
Zhu L, Jiang L, Yang J, et al. Clinical characteristics and prognosis of patients with lung adenosquamous carcinoma after surgical resection: results from two institutes[J]. J Thorac Dis, 2018, 10(4): 2397-2402.
|
| 6 |
Zhao WJ, Wang X, Ma KW. Progression of diagnosis and treatment for adenosquamous lung carcinoma[J]. Zhonghua Zhong Liu Za Zhi 2017, 39(4): 241-244.
|
| 7 |
Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: International Multidisciplinary Classification of Lung Adenocarcinoma: Executive Summary[J]. Proc Am Thorac Soc, 2011, 8(5): 381-385.
|
| 8 |
Travis WD, Brambilla E, Burke AP, et al. Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart[J]. J Thorac Oncol, 2015, 10(9): 1240-1242.
|
| 9 |
Wang J, Wang Y, Tong M, et al. Research progress of the clinicopathologic features of lung adenosquamous carcinoma[J]. Onco Targets Ther, 2018, 11: 7011-7017.
|
| 10 |
Noronha V, Patil VM, Joshi A, et al. Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer[J]. J Clin Oncol, 2019, 38(2): 124-136.
|
| 11 |
Wu SG, Shih JY. Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer[J]. Mol Cancer, 2018, 17(1): 38.
|
| 12 |
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
|
| 13 |
Shi Y, Au SK, Thongprasert S, et al. A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)[J]. J Thorac Oncoly, 2014, 9(2): 154-162.
|
| 14 |
William P, Juliann C. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer[J]. Nat Rev Cancer, 2010, 11(10): 760.
|
| 15 |
Wu YL, Cheng Y, Zhou XD, et al. Dacomitinib versus gefitinib as firstline treatment for patients with, EGFR -mutation-positive non-smallcell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2017, 18(11): 1454-1466.
|
| 16 |
Kancha RK, von Bubnoff N, Peschel C, et al. Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy[J]. Clin Cancer Res, 2009, 15(2): 460-467.
|
| 17 |
Kobayashi Y, Togashi Y, Yatabe Y, et al. EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs[J]. Clin Cancer Res, 2015, 21(23): 5305-5313.
|
| 18 |
Banno E, Togashi Y, Nakamura Y, et al. Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor?[J]. Cancer Sci, 2016, 107(8): 1134-1140.
|
| 19 |
Kohsaka S, Nagano M, Ueno T, et al. A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer[J]. Sci Transl Med, 2017, 9(416): 6554-6566.
|
| 20 |
Yang CH, Sequist LV, Geater SL, et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6[J]. Lancet Oncol, 2015, 16(7): 830-838.
|
| 21 |
Chiu CH, Yang CT, Shih J Y, et al. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations[J]. J Thorac Oncol, 2015, 10(5): 793-799.
|
| 22 |
Xu J, Jin B, Chu T, et al. EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China[J]. Lung Cancer, 2016, 96: 87-92.
|
| 23 |
Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer[J]. N Engl J Med, 2018, 378(2): 113.
|
| 24 |
Wu YL, Tsuboi M, He J, et al. Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer[J]. N Engl J Med, 2020, 383(18): 1711-1723.
|